While programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have revolutionized the management of advanced NSCLC and improved patient survival, but the elderly display prominent immunosenescence features. This evidence concerns the gene CD274 and non-small cell lung carcinoma.